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ÖZ
Amaç: Çocuklarda, oksidan ve antioksidan dengenin kistik fibrosis 
dışı bronşiekatazi (non-CF BE) patogenezi ve prognozundaki 
etkisinin değerlendirilmesi.
Gereç ve Yöntem: Haziran 2009 ve Ekim 2010 tarihleri arasında non-
CF BE tanılı 29 çocuk çalışmaya alındı. Otuz sağlıklı çocuk kontrol 
grubunu oluşturdu. Sağlıklı ve hasta çocuklarda paraoksonaz1 
(PON1), total oksidan durum (TOS) ve total antioksidan durum 
(TAS) serum düzeyleri stabil ve alevlenme dönemlerinde ölçüldü.
Bulgular: Hasta grubunda PON1 ve TAS düzeyleri alevlenme 
döneminde kontrol gurbuna göre daha düşüktü (p= 0.05 ve p= 0.01, 
sırasıyla). İmmün yetmezlikli hastalarda oksidatif stresi gösteren 
TOS düzeyleri ve TAS/TOS oranı kontrol grubuna göre daha 
düşüktü (p= 0.008 ve p= 0.01, sırasıyla). TAS düzeyleri ve PON1/
TOS oranı orta-şiddetli bronşiektazili hastalarda hafif bronşektazili 
hastalardan daha düşüktü (p= 0.04 ve p= 0.03, sırasıyla).
Sonuç: Alevlenme döneminde non-CF BE çocuklarda oksidatif 
stres artmış ve anti-oksidan kapasite azalmıştır. Antioksidan tedavi 
özellikle immün yetmezliği ve/veya orta-şiddetli bronşiaktazisi 
olan non-CF BE hastalarda oksidatif stresin neden olduğu hasarın 
şiddetini azaltmaya yardımcı olacak, özellikle daha iyi prognoza 
katkıda bulunacaktır. 
ABSTRACT
Objective: To evaluate the role of the oxidant and antioxidant 
balance in the pathogenesis and prognosis of non-cystic fibrosis 
bronchiectasis (non-CF BE) in children.
Materials and Methods: Twenty-nine children with non-CF BE 
were enrolled between June 2009 and October 2010. Thirty healthy 
children were enrolled as controls. Paraoxonase 1 (PON1), total 
oxidant status (TOS), and total antioxidant status (TAS) serum levels 
were measured in controls and in patients when stable and at acute 
exacerbation.
Results: PON1 and TAS levels were lower in patients at acute 
exacerbation than in controls (P= 0.05 and P= 0.01, respectively). 
TOS levels indicative of oxidative stress were higher, and TAS/
TOS levels were lower, in immune-deficient patients than control 
group (P= 0.008 and P= 0.01, respectively). TAS levels and PON1/
TOS ratio were significantly lower in patients with moderate–severe 
bronchiectasis than in patients with mild bronchiectasis (P= 0.043 
and P= 0.03, respectively).
Conclusion: Oxidative stress was increased and antioxidant capacity 
decreased in patients with non-CF BE during the exacerbation 
period. Antioxidant treatment in patients with non-CF BE, especially 
in patients with immunodeficiency and/or with moderate–severe 
bronchiectasis, could be helpful to reduce the frequency and 
severity of the attacks by reducing oxidative stress-induced damage, 
ultimately contributing to a better prognosis.
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INTRODUCTION
Bronchiectasis is a chronic inflammatory disease of 
the bronchial wall characterized by congenital or acquired 
irreversible dilation (1). In developed countries, the 
most common cause is cystic fibrosis with other types 
of bronchiectasis being defined as non-cystic fibrosis 
bronchiectasis (non-CF BE). At tissue level, bronchiectasis 
is considered to arise from inflammatory destruction of 
muscle, elastic tissue, and bronchial wall cartilage resulting 
from long-term contact of inflamed mucoid fluid with the 
bronchial wall (2,3).
Free radical production and elimination rates are well 
balanced under physiological conditions. This balance 
is known as oxidative balance. However, an increase in 
the production rate or a decrease in the elimination rate 
leads to imbalance between free radical production and 
antioxidant defense mechanisms, thereby causing tissue 
injury (4-6). This imbalance is known as oxidative stress. 
If not neutralized, free radicals degrade cellular membrane 
proteins, inhibit cellular functions, and make DNA 
susceptible to breaks and mutations by affecting nuclear 
genetic material. Chronic diseases and cell death occur as 
the result of oxidative stress and subsequent tissue injury.
Paraoxonase (PON) is an enzyme associated with 
high-density lipoproteins that exerts antioxidant effects by 
inhibiting fatty acid oxidation in low-density lipoproteins. 
Increased lipid and protein oxidation products and oxidative 
stress caused by a reduction in antioxidant enzymes and 
vitamins reduce PON level. An organism’s oxidant–
antioxidant balance can be determined by measuring the 
antioxidant enzyme activity and the oxidant/antioxidant 
level, but an easier way is to measure the total oxidant status 
(TOS) and the total antioxidant status (TAS). Oxidants 
and antioxidants are involved in the pathogenesis of many 
renal, pulmonary, cardiac, hematologic, and neurologic 
diseases. Studies based on the measurement of oxidants and 
antioxidants have been conducted for pulmonary diseases 
such as chronic obstructive pulmonary disease (COPD), 
tuberculosis, and cystic fibrosis (7-11). In this study, we 
evaluated the role of the oxidant and antioxidant balance 
in the pathogenesis and prognosis of pediatric non-cystic 
fibrosis bronchiectasis (non-CF BE) by measuring serum 
PON1, TAS, and TOS levels.
MATERIALS and METHODS
A total of 29 patients who were being followed up at the 
Division of Pediatric Pulmonology of Necmettin Erbakan 
School of Medicine were included in this prospective 
case-control study between June 2009 and October 2010. 
Twenty-nine patients were evaluated at acute exacerbation 
and 28 cases were evaluated during the stable period 
following exacerbation (one patient died during the 
exacerbation period). Thirty healthy children whose age 
and sex were matched to the study group and who were 
admitted to a general pediatrics clinic for regular check-up 
and did not have any diseases were included as controls.
Ethics committee approval was obtained from 
Necmettin Erbakan University Meram School of Medicine. 
Support was provided by Scientific Research Projects of 
Necmettin Erbakan University. All parents were informed 
about the content and aim of the study, and informed 
consent was obtained. Patients whose parents did not agree 
to participate and those who had cystic fibrosis-related 
bronchiectasis were excluded from the study.
Date of participation, age, sex, height, weight, 
percentiles, body mass index (BMI), body temperature, 
respiratory rate, oxygen (O2) saturation, physical 
examination findings, smoking status at home, number 
of family members, status of chest physiotherapy, yearly 
influenza vaccination status, duration of follow-up, and 
duration of therapy during the exacerbation period were 
recorded at acute exacerbation. Height, weight, percentiles, 
BMI, body temperature, respiratory rate, O2 saturation, 
and physical examination findings were recorded again 
during the stable period.
Increase in sputum production, change in the 
quality of sputum, increase in cough, dyspnea, fever, 
elevated C-reactive protein (CRP), procalcitonin, and 
novel infiltration on chest radiography were accepted as 
exacerbation criteria. Postero-anterior chest radiography, 
Anahtar kelimeler: Çocuk, kistik fibrosis dışı bronşiektazi, oksidatif 
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complete blood count, erythrocyte sedimentation rate 
(ESR), CRP, procalcitonin, sputum culture, and blood 
gas analysis were obtained from the patients in order to 
determine the exacerbation criteria. Respiratory function 
test was performed in patients compliant to the test. 
During this period, patients received antibiotic therapy for 
14 days either in outpatient or in inpatient setting.
Previously or newly obtained tomographic scans of all 
patients were evaluated. Anatomic spread of bronchiectasis 
was evaluated by a radiologist blinded to the clinical 
condition of the patients and scored individually for each 
lobe: grade 0, no bronchiectasis findings; grade 1, mild 
bronchiectasis (<25% of the lobe); grade 2, moderate 
bronchiectasis (25–50% of the lobe); grade 3, severe 
bronchiectasis (> 50% of the lobe). Scores of all lobes 
were summed up and an overall score was obtained 
according to the severity of bronchiectasis (11). A total 
score of 0–6 indicated mild bronchiectasis, 7–12 indicated 
moderate bronchiectasis, and 13–18 indicated widespread 
bronchiectasis.
Auscultation findings were recorded separately as 
crackles and rhonchi according to zones. Crackles were 
not classified according to being inspiratory or expiratory 
or to type.
Blood (5 cc) was withdrawn from controls and from 
patients with bronchiectasis at acute exacerbation and 1 
month following antibiotherapy, during the stable period. 
Blood was centrifuged at 2500 rpm for 10 min and sera 
were separated. Serum samples were stored at -80°C until 
use. PON1, TOS, and TAS levels were determined at the 
Central Laboratory of Biochemistry, Necmettin Erbakan 
University Meram School of Medicine.
Paraoxone was used as substrate for measurement of 
PON1 activity and absorbance of the color formed upon 
hydrolysis of paraoxone was recorded at 412 nm and 37°C. 
Paraoxonase activity was measured as basal activity and 
results were given in U/L. TOS was determined by using 
an automatized measurement method (12,13). Oxidants 
in the sample convert ferrous ion-o-dianisidine to ferric 
ion. Ferric ion forms a color complex with xylenol orange 
in an acidic environment. Density of the color measured 
spectrophotometrically is related with the total amount 
of oxidant molecules. Measurement was calibrated with 
hydrogen peroxide (H2O2) and the results were given in 
µmol H2O2 equiv/L (12,13). TAS was determined with an 
automatized measurement method based on the formation 
of a characteristic pale color upon addition of antioxidants 
to a solution containing 2,2’-azino-bis (3-ethylbenz-
thiazoline-6-sulfonic acid) (ABST). Results were given in 
mmol Trolox equivalent/L (12,13).
The Statistical Package for the Social Sciences (SPSS) 
for Windows version 15.0 was used as the statistical 
analysis program to assess the data. Tests of normality 
were conducted to compare the general characteristics 
between patients and controls. The chi-square and Fisher’s 
exact test was used to compare the differences between 
the frequency rates of the categorical data. Student’s t test 
and the Mann–Whitney U test were used to compare the 
difference between the averages of the data that did and 
did not comply with normal distribution, respectively. For 
repetitive measurements, one-way analysis of variance was 
used. Statistical significance was set at P<0.05, and the 
confidence interval (CI) was determined at a 95% level.
RESULTS
Of 29 patients with non-CF BE, 14 (48.3%) were boys 
and 15 (51.7%) were girls. Their mean age was 10.55 ± 4.31 
years (16–202 months). The control group consisted of 14 
(46.7%) boys and 16 (53.3%) girls. There was no statistically 
significant difference between groups in terms of age and 
sex (P > 0.05).
A respiratory function test could not be done in five 
patients due to non-compliance to the test. Decreased 
FEV1 (<80%) was detected in 18 patients (75%), decreased 
FVC (<80%) was detected in 19 patients (79.1%), and 
decreased FEF25–75% (<80%) was detected in 23 patients 
(95.8%). Body weight, BMI, FEV1, FVC, FEF25–75%, pO2 
values of non-CF BE patients were significantly higher 
during the stable period than during the exacerbation 
period (P<0.05). Fever, respiratory rate, white blood cell 
count, neutrophil and lymphocyte ratios, ESR, and CRP 
values were significantly lower during the stable period 
than during the exacerbation period (P<0.05). Weight 
gain was significantly higher during the stable period (P= 
0.001).
There was no statistically significant difference between 
the exacerbation and stable periods in terms of height, 
procalcitonin, and FEV1/FVC ratio (P > 0.05) (Table I).
Complaints reported during the exacerbation period 
were cough (100%), increased sputum (93.1%), change in 
the color of sputum (79.3%), dyspnea (44.8%), fever (31%), 
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fatigue (31%), hemoptysis (6.9%), and chest pain (3.4%). 
Physical examination findings during the exacerbation 
period were as follows: crepitant rale (24 patients [82.7%]), 
rhonchus (17 patients [58.6%]), dyspnea (13 patients 
[44.8%]), decreased O2 saturation (≤ 92%) (11 patients 
[37.9%]), fever (9 patients [31.0%]), tachypnea (9 patients 
[31%]), and decreased respiratory sounds (3 patients 
[10.3%]). Chest deformity and clubbing were detected in 
9 (31%) and 5 patients (17.2%), respectively. Six patients 
(20.6%) had undergone surgery for bronchiectasis.
Distribution of cases according to etiology was as 
follows: previous lung infection (14 patients [48.3%]), 
asthma (8 patients [27.6%]), immune deficiency (4 
patients [13.8%]), tuberculosis (1 patient [3.4%]), Swyer–
James syndrome (1 patient [3.4%]), and primary ciliary 
dyskinesis (1 patient [3.4%]).
Anatomic spread of bronchiectasis was as follows: mild 
(24 patients [82.7%]), moderate (4 patients [13.8%]), and 
severely widespread (1 patient [3.4%]).
PON1 and TAS levels indicative of antioxidant activity 
were decreased during the exacerbation period in non-CF 
BE patients compared to controls. Although not statistically 
significant, TOS levels indicative of oxidant activity 
were elevated slightly during the exacerbation period 
in non-CF BE patients compared to controls. Although 
not statistically significant, PON1 and TAS levels were 
decreased slightly, and TOS levels did not change during 
the exacerbation period compared to the stable period. 
Therefore, antioxidant activity appears to be decreased 
slightly in non-CF BE patients at acute exacerbation 
compared to the stable period (Table II). PON1, TOS, and 
TAS levels were similar in non-CF BE patients during the 
stable period and in controls (P= 0.33, P= 0.89, and P= 
0.33, respectively). PON1/TOS level was higher in controls 
than in non-CF BE patients; among non-CF BE patients, 
PON1/TOS level was higher during the stable period than 
at acute exacerbation. PON1/TOS, and TAS/TOS levels 
were similar between groups (Table II).
When patients were classified according to the etiology 
of bronchiectasis, TOS levels indicative of oxidative stress 
were higher (P= 0.008), and TAS/TOS level was lower (P= 
0.01), in immune-deficient patients. PON1 levels were 
lower in immune-deficient patients compared to other 
groups, but not significantly so (Table II).
Oxidative balance was evaluated according to severity 
of bronchiectasis based on thoracic computed tomography 
scores. Serum TAS and PON1/TOS levels were significantly 
lower in patients with moderate–severe bronchiectasis 
compared to patients with mild bronchiectasis (P= 0.043 
and P= 0.03, respectively). Although TAS/TOS and PON1 
levels were lower and TOS levels were higher in patients 
with moderate–severe bronchiectasis, the differences 
were not statistically significant (Table II). It is possible 
that oxidative stress increases as the anatomic spread of 
bronchiectatic areas increases, but antioxidant capacity is 
insufficient.
There were no correlations between the FEV1 and 
PON1(r=-0.03; p=0,69), FEV1 and TAS (r=-0.05; p=0.81), 
FEV1 and TOS (r=-0.10; p=0,66), FVC and PON1 (r=0,23; 
p=0.33), FVC and TAS (r=0,08; p=0,71), FVC and TOS 
(r=-0.11; p=0.61). 
Table I. Clinical and laboratory characteristics of patients 
with non-CF BE during both exacerbation and stable 
periods
Exacerbation
(n=29)
Stable
(n=28)
Body weight (kg) 32.43 ± 16.14* 33.16 ± 16.48
Height (cm) 135.36 ± 24.47 136.11 ± 24.14
BMI (kg/m2) 16.36 ± 3.10* 16.65 ± 3.21
Body temperature (°C) 37.31 ± 0.91* 36.91 ± 0.21
Respiratory rate (/min) 28.75 ± 8.80* 22.79 ± 2.82
WBC count (/mm3) 11851 ± 5061* 7600 ± 2360
PMNL (%) 64.39 ± 16.44* 58.34 ± 7.95
Lymphocyte (%) 25.71 ± 14.42* 30.37 ± 7.89
ESR (mm/h) 33.64 ± 23.45* 12.75 ± 8.55
CRP (mg/dL) 36.43 ± 30.54* 4.73 ± 2.40
Procalcitonin (ng/mL)a 0.08 (0.02–0.50) 0.04 (0.01–0.45)
pO2 (mmHg) 86.93 ± 5.06* 92.00 ± 3.32
FEV1 61.54 ± 22.87* 68.92 ± 24.02
FVC 69.33 ± 21.39* 75.25 ± 19.63
FEV1/FVC 81.92 ± 11.94 83.46 ± 12.04
FEF25–75% 50.75 ± 24.91* 57.67 ± 27.52
Data are the mean ± standard deviation.
a Median (minimum–maximum), * P<0.05
BE: Bronchiectasis, BMI: Body mass index, WBC: White blood 
cell, PMNL: Polymorphonuclear leukocyte, ESR: Erythrocyte 
sedimentation rate, CRP: C-reactive protein, FEV1: Forced 
expiratory volume in one second, FVC: Forced vital capacity, 
FEF25–75%: Forced expiratory flow 25–75%.
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DISCUSSION
The incidence of bronchiectasis is approximately 
5/1.000.000 in the pediatric population, 1/25000 in patients 
aged 18–34 years, and 272/100.000 in patients aged 75 
years and older. Its prevalence is estimated to be higher in 
developing countries (14-19).
Proteases and toxic oxygen radicals released from 
neutrophils that have migrated to the inflammation site 
have been shown to result in the inflammatory destruction 
of smooth muscle, elastic tissue, and the cartilage structure 
of the bronchial wall, injury to the ciliary structures, and 
gland hypersecretion (2,20). If oxygen radical formation 
exceeds the capacity of the antioxidant defense system under 
oxidative stress, increased free oxygen radicals interact with 
various cellular and extracellular components, resulting 
in structural and functional impairment. This imbalance 
may occur in favor of either oxidants or antioxidants 
(6,20). TAS reflects the total effect of antioxidants in 
plasma and body fluids, whereas TOS reflects the total 
effect of oxidants. Although oxidant–antioxidant/oxidant 
status can be determined by measuring oxidant and 
antioxidant molecules separately, these measurements are 
time consuming, costly, and complex. Therefore, we chose 
to determine the oxidant–antioxidant/oxidant status by 
measuring TOS and TAS.
Infections lead to oxidative damage by facilitating 
accumulation and activation of phagocytic cells in the lungs. 
However, increased O2 production during the exacerbation 
period declines to normal levels during the stable period in 
COPD patients (10). In our study, PON1 and TAS levels 
were found to be lower during the exacerbation period 
than during the stable period in patients with non-CF BE.
Increased oxidative stress and decreased antioxidant 
system were studied in children with asthma, allergic 
rhinitis, and cystic fibrosis; and in adults with COPD, 
bronchiectasis, emphysema, and asthma (21). However, 
the number of studies in children is limited. In a study with 
25 patients with pulmonary tuberculosis and 33 healthy 
controls, Selek et al. (22) found that PON, arylesterase, 
and total free sulfydryl levels were lower, and TOS and 
lipid hydroperoxide levels were higher in patients than 
in controls. Rai et al. (23) reported that oxidant and 
antioxidant status varied across different respiratory 
diseases. Malondialdehyde (MDA)—an indicator of plasma 
oxidant status—is significantly increased in patients with 
COPD, emphysema, bronchiectasis, and bronchial asthma. 
Antioxidant vitamins, namely vitamin E and vitamin C, 
are lower in those patients than in controls. Similarly, in 
our study, PON1 and TAS levels were lower in non-CF BE 
patients at acute exacerbation than in controls (decreased 
antioxidant activity), but TOS values were higher 
Table II. Comparison of PON1, TOS, TAS, PON1/TOS (antioxidant status), and TAS/TOS (oxidant status) levels of non-CF BE 
patients according to periods, etiology, and severity of bronchiectasis
PON1 TAS TOS PON1/TOS TAS/TOS
Type
Exacerbation 47.67 ± 31.48* 1.96 ± 0.35* 40.22 ± 26.67 2.10 ± 2.02 0.08 ± 0.05
Stable 52.01 ± 34.96* 2.14 ± 0.37* 40.78 ± 26.20 1.81 ± 1.51 0.07 ± 0.03
Control 66.55 ± 45.06* 2.16 ± 0.27* 37.30 ± 19.21 2.56 ± 2.82 0.08 ± 0.05
Etiology
PPE 39.90 ± 22.91 2.04 ± 0.44 31.47 ± 18.78** 1.89 ± 1.68 0.09 ± 0.05**
ID 26.57 ± 14.65 1.98 ± 0.44 84.86 ± 14.22** 0.31 ± 0.15 0.02 ± 0.01**
Asthma 62.67 ± 41.62 1.93 ± 0.45 35.12 ± 22.32** 2.90 ± 2.57 0.07 ± 0.04**
Tx CT score
0–6 49.57 ± 30.10 2.02 ± 0.35*** 37.63 ± 26.79 1.31 ± 1.07*** 0.05 ± 0.03
7–18 29.76 ± 35.70 1.67 ± 0.21*** 52.99 ± 24.24 0.56 ± 0.45*** 0.03 ± 0.02
PPE: Previous pulmonary infection, ID: Immunodeficiency, Tx CT: Thoracic computed tomography.
* PON1 and TAS levels were lower at exacerbation than in controls (P= 0.05 and P= 0.01, respectively)
** TOS level was higher, and TAS/TOS level was lower, in the ID group than in other groups (P= 0.008 and P= 0.01, respectively)
*** TAS and PON1/TOS levels were lower in the moderate–severe BE group than in the mild BE group (P= 0.04 and P= 0.03, respectively).
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(increased oxidant activity). Impairment of oxidant–
antioxidant balance is common in cystic fibrosis patients, 
as inflammation and infection are constantly present (24). 
However, there is no constant inflammation in non-CF 
BE. Elevated oxidative stress was shown not only in lung 
tissue but also in circulation of children with asthma and 
cystic fibrosis-related bronchiectasis (25). Horvath et al. 
(26) suggested carbon monoxide as an oxidative stress 
marker in bronchiectasis patients; indeed, its levels were 
shown to be high in exhaled air despite anti-inflammatory 
therapy. Rahman et al. (27) reported lower plasma TAS 
levels in asthma patients than in controls. Stanojkovic et 
al. (28) found that TOS levels were elevated but returned to 
normal during the activation period in COPD patients; on 
the other hand, TAS levels were lower than normal both in 
activation and stable periods, and PON1 enzymatic activity 
was similar to that of controls. In a study by Gumral et al. 
(29), for the patients with bronchial asthma and chronic 
obstructive pulmonary disease, oxidative stress was found 
to increase both in activation and stable periods, while 
antioxidant enzymes were decreased. Similar results were 
obtained in non-CF BE patients both in activation and 
stable periods in our study. Two possible explanations 
are the induction of oxidative stress in the lung due to 
inflammation and the impairment of oxidant–antioxidant 
balance.
In a study by Olveira et al. (20), oxidative stress was 
increased, and antioxidant capacity was decreased, in 90 
adult patients with bronchiectasis. No difference was found 
between cystic fibrosis-related bronchiectasis and non-
CF BE. In our study, TOS level and oxidative stress were 
significantly higher (P= 0.008) in patients with immune 
deficiency compared to patients who had recurrent 
pulmonary infections and asthma with causes other 
than immune deficiency. Immune-deficient patients are 
more commonly exposed infections and thus to constant 
oxidative stress. It is possible that the antioxidant system is 
unable to cope with constant oxidative stress.
In this study, another factor affecting oxidative stress 
was the extent of the bronchiectatic area. Oxidative stress 
increased, and antioxidant capacity decreased, as the 
bronchiectatic area increased. To our knowledge, no other 
studies have reported similar findings. On the contrary, 
Palop-Cervera et al. (30) failed to identify a relationship 
between inflammation markers in the exhaled air and the 
severity of clinical and radiologic findings, respiratory 
function tests, quality of life; however, the authors found a 
relationship between inflammation markers and bacterial 
colonization.
In a study with asthma patients, Guo et al. (31) showed 
that nutritional support improves oxidant–antioxidant 
imbalance, inflammation, immune response, and 
pulmonary functions. We also consider that antioxidant 
or nutritional supplement administration would positively 
affect the prognosis of pediatric non-CF BE patients during 
the exacerbation period, with positive consequences to the 
quality of life.
The results of our study suggested that changes in 
PON1 activity could play a role in the pathogenesis of 
bronchiectasis, and that elevated TOS and decreased TAS 
levels could be the pathologic result of oxidative stress in 
bronchiectasis. Therefore, we suggest that plasma TOS and 
TAS levels, especially PON1/TOS levels, may be used as 
inflammation markers depending on the presence and the 
degree of inflammation in bronchiectasis patients. These 
markers’ being elevated in widespread bronchiectasis may 
reflect prognosis during follow-up and even radiation 
exposure of children if oxidative stress markers stay 
stable during stable periods. Studies conducted with 
more patients are needed to understand progression of 
bronchiectasis through measurement of total oxidative 
stress and total antioxidant capacity measurement. 
Understanding the mechanism of action of oxidative stress 
in COPD, bronchiectasis, and other lung diseases would 
enable future potent antioxidant therapies.
In conclusion, oxidative stress increased, and antioxidant 
capacity decreased, in patients with non-CF BE at acute 
exacerbation. Antioxidant treatment in patients with non-
CF BE, especially in patients with immunodeficiency and/
or with moderate–severe bronchiectasis, could be helpful 
to reduce the frequency and severity of the attacks.
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